{"id":"W3136768966","doi":"10.1016/j.clgc.2021.03.006","title":"Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Health Services; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto; University of Calgary","funders":"Mailman School of Public Health, Columbia University; Pfizer Canada; Genentech; Astellas Pharma; Bristol-Myers Squibb Canada; Eisai; Ipsen; Astellas Pharma Canada; Roche; EMD Serono; Novartis; AstraZeneca; Amgen; Pfizer; Exelixis; Meso Scale Diagnostics; Sanofi; MedImmune; Merck; GlaxoSmithKline","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Oncology; Internal medicine; Clinical Oncology; Kidney cancer; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001641404,0.0002861125,0.0007623397,0.0005109013,0.0003520316,0.0009999927,0.0004304053,0.0005372208,0.0008956993],"category_scores_gemma":[0.003400548,0.0001760668,0.0009045398,0.0007035247,0.0003515779,0.0005960242,0.0003657401,0.0004277868,0.0002024141],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009048114,"about_ca_system_score_gemma":0.0005778113,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001667185,"about_ca_topic_score_gemma":0.0022699,"domain_scores_codex":[0.9985836,0.0005179296,0.0001739855,0.0003393832,0.000264294,0.0001209003],"domain_scores_gemma":[0.995104,0.0008652742,0.003134795,0.0001904933,0.000262013,0.0004434185],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001921873,0.0002346675,0.9935083,0.00007461455,0.000258783,0.0001405158,0.0000555991,0.0001558226,0.0002318013,0.000009176027,0.00009492642,0.003313886],"study_design_scores_gemma":[0.0003147391,0.003099776,0.9934298,0.00002531059,0.0002510214,0.001232602,0.0001176178,0.000610346,0.0002852162,0.00001472293,0.0006041175,0.0000147497],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9986922,0.0007923752,0.00003709429,0.00002383817,0.000003429265,0.00001864709,0.0002538481,0.000002476952,0.0001760656],"genre_scores_gemma":[0.9991935,0.0002013525,0.00004857935,0.00003210975,0.00001450287,0.00001370348,0.0004632754,0.000001166456,0.00003177037],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001667185,"threshold_uncertainty_score":0.008680701,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0731584245030044,"score_gpt":0.4054384180125898,"score_spread":0.3322799935095854,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}